{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"133-707-600-616-098","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"133-707-600-616-098"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11655,"type":"PATENT","title":"University of Freiburg - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":2803,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8321,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:uni* freiburg
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 2438
Search Applicants and Owners separately:Med* Univ* wien. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 364
Search Applicants and Owners separately:uni* freiburg
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 2438
Search Applicants and Owners separately:Med* Univ* wien. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 364
Xxx1-Leu-Pro-Val-Cys-Gly-Glu-Xxx2-Cys-Xxx3-Gly-Gly-Thr-Cys-Asn-Thr-Pro-Xxx1-Cys-Xxx1-Cys-Xxx1-Trp-Pro-Xxx1-Cys-Thr-Arg-Xxx1 (SEQ ID NO: 17);\n\nwherein each Xxx1 position independently comprises any amino acid, non-natural amino acid or peptidomimetic;\nwherein Xxx2 comprises an amino acid non-natural amino acid or peptidomimetic but not Lys;\nwherein Xxx3 comprises any amino acid, non-natural amino acid or peptidomimetic but not Ala or Lys;\n
wherein the mutated cyclotide comprises one or more mutations from the naturally occurring kalata B1 cyclotide (SEQ ID NO:1),\n
wherein said cyclotide comprising an amino acid sequence that is at least 90% identical to the amino acid sequence SEQ ID NO:7, and\n
wherein the amino acid sequence of said cyclotide carries a mutation at least one amino acid position corresponding to an amino acid position which has been mutated in any one of the mutated cyclotides as depicted in SEQ ID NO: 5, 6 or 7."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The mutated cyclotide of claim 1, wherein said mutation is G→K at position 1, T→K at position 20, and/or N→K at position 29."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["A cyclotide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 6, and 7."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["A mutated cyclotide having immunosuppressive activity, said cyclotide comprising an amino acid sequence of formula IL wherein formula II comprises:\n
Xxx1-Leu-Pro-Val-Cys-Gly-Glu-Xxx2-Cys-Xxx3-Gly-Gly-Thr-Cys-Asn-Thr-Pro-Xxx1-Cys-Xxx1-Cys-Xxx1-Trp-Pro-Xxx1-Cys-Thr-Arg-Xxx1 (SEQ ID NO:17);\n\nwherein each Xxx1 position independently comprises any amino acid, non-natural amino acid or peptidomimetic;\nwherein Xxx2 comprises an amino acid non-natural amino acid or peptidomimetic but not Lys;\nwherein Xxx3 comprises any amino acid, non-natural amino acid or peptidomimetic but not Ala or Lys;\n
wherein the cyclotide comprises one or more mutations from the naturally occurring kalata B1 cyclotide (SEQ ID NO:1),\n\nwherein the cyclotide comprises an amino acid sequence having one or more of amino residues at amino acid positions 1, 18, 20, 22, 25, and/or 29 of SEQ ID NO:17 representing a different amino acid from the same position of SEQ ID NO:1, and\n
wherein said at least one amino acid position corresponds to:\n"],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["A mutated cyclotide having immunosuppressive activity, said cyclotide comprising an amino acid sequence of formula IL wherein formula II comprises:\n(i) amino acid position 29 of the mutated cyclotide SEQ ID NO: 5;\n(ii) amino acid position 1 of the mutated cyclotide SEQ ID NO. 6;\n(iii) amino acid position 20 of the mutated cyclotide SEQ ID NO. 6; or\n(iv) amino acid position 20 of the mutated cyclotide as depicted in SEQ ID NO: 7.\n
Xxx1-Leu-Pro-Val-Cys-Gly-Glu-Xxx2-Cys-Xxx3-Gly-Gly-Thr-Cys-Asn-Thr-Pro-Xxx1-Cys-Xxx1-Cys-Xxx1-Trp-Pro-Xxx1-Cys-Thr-Arg-Xxx1 (SEQ ID NO: 17);\n\nwherein each Xxx1 position independently comprises any amino acid, non-natural amino acid or peptidomimetic;\nwherein Xxx2 comprises an amino acid non-natural amino acid or peptidomimetic but not Lys;\nwherein Xxx3 comprises any amino acid, non-natural amino acid or peptidomimetic but not Ala or Lys; and\n
wherein the mutated cyclotide comprises one or more mutations from the naturally occurring kalata B1 cyclotide (SEQ ID NO:1), and\n
wherein said mutation is G→K, T→K, S→K, N→K, or D→K."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The mutated cyclotide of claim 1, wherein the amino acid sequence of said cyclotide is radio labelled, fluorescence-labelled or biotin-labelled."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising the mutated cyclotide of claim 1 and a pharmaceutically acceptable carrier, excipient or diluent."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 7, wherein said pharmaceutical composition further comprises one or more additional immunosuppressants."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 8, wherein said additional immunosuppressant comprises Cyclosporine A, Muromonab-CD3 or Basiliximab."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["A method for immunosuppression, the method comprising administering an effective amount of a non-grafted mutated cyclotide to a subject in need thereof, said cyclotide comprising an amino acid sequence of formula IL wherein formula II comprises:\n
Xxx1-Leu-Pro-Val-Cys-Gly-Glu-Xxx2-Cys-Xxx3-Gly-Gly-Thr-Cys-Asn-Thr-Pro-Xxx1-Cys-Pro-Xxx1-Cys-Thr-Arg-Xxx1 (SEQ ID NO: 17);\n
wherein each Xxx1 position independently comprises any amino acid, non-natural amino acid or peptidomimetic;\n
wherein Xxx2 comprises any amino acid, non-natural amino acid or peptidomimetic but not Lys;\n
wherein Xxx3 comprises any amino acid, non-natural amino acid or peptidomimetic but not Ala or Lys; and\n
wherein the mutated cyclotide comprises one or more mutations from the naturally occurring kalata B1 cyclotide (SEQ ID NO:1)."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, wherein said mutation is X→K, wherein X is any amino acid."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, wherein said cyclotide has an anti-proliferative effect on (an) immune cell(s) and/or suppresses/reduces the effector function(s) of (an) immune cell(s)."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, wherein said cyclotide is administered so that cytostatic but no cytotoxic activity occurs."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, wherein said cyclotide is administered in an amount to reach a serum concentration in the range of 1 to 50 μM."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, wherein said pharmaceutical composition further comprises one or more additional immunosuppressants."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 15, wherein said additional immunosuppressant comprises Cyclosporine A, Muromonab-CD3 or Basiliximab."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, for the treatment of a subject suffering from a disorder selected from the group consisting of an autoimmune disorder, a hypersensitivity disorder, and a lymphocyte-mediated inflammation."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17, wherein said autoimmune disorder is selected from the group consisting of Multiple Sclerosis, Psoriasis, Systemic Lupus Erythematosus, Sjögren's syndrome, Rheumatoid Arthritis, Idiopathic Thrombocytopenic Purpura, Diabetes, Vasculitis, and Crohn's disease."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17, wherein said lymphocyte-mediated inflammation comprises a T cell-mediated inflammation."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17, wherein said lymphocyte-mediated inflammation comprises Keratoconjunctivitis sicca or Dry Eye Syndrome (DES)."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, wherein:\n
the proliferation of (an) immune cell(s);\n
the effector function(s) of (an) immune cell(s);\n
the degranulation/cytotoxicity of (an) immune cell(s);\n
the expression of a cytokine surface receptor on (an) immune cell(s);\n
the proliferation of (primary) activated lymphocytes;\n
the proliferation of peripheral blood mononuclear cells (PBMC);\n
secretion/production of IL-2, IFN-gamma and/or TNF-alpha;\n
degranulation/cytotoxicity of CD107a+ CD8+ PBMCs; and/or\n
expression of IL-2 surface receptor CD25 is/are suppressed."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, wherein said cyclotide\n
suppresses/reduces secretion/production of IL-2, IFN-gamma and/or TNF-alpha;\n
suppresses/reduces degranulation/cytotoxicity of CD107a+ CD8+ PBMCs; and/or\n
suppresses/reduces expression of IL-2 surface receptor CD25."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, wherein the anti-proliferative effect or suppression/reduction is mediated in an IL-2-, IFN-gamma- and/or TNF-alpha-depending manner and/or can be antagonized by IL-2."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["A method of producing an immunosuppressive pharmaceutical composition comprising mixing a mutated cyclotide of claim 1 with a pharmaceutically acceptable carrier."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, said cyclotide comprising an amino acid sequence having one or more of amino residues at amino acid positions 1, 18, 20, 22, 25, and/or 29 of SEQ ID NO:17 representing a different amino acid from the same position of SEQ ID NO:1."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, said cyclotide comprising an amino acid sequence that is:\n
at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs:5, 6, or 7; or\n
at least 90% identical to an amino acid sequence encoded by a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NOs:5, 6, or 7;\n
wherein the amino acid sequence of said cyclotide carries a mutation at least one amino acid position corresponding to an amino acid position which has been mutated in any one of the mutated cyclotides as depicted in SEQ ID NO: 5, 6 or 7."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, said cyclotide comprising an amino acid sequence that is at least 90% identical to the amino acid sequence SEQ ID NO:7."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, said cyclotide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence SEQ ID NO:7."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 14, wherein said cyclotide is administered in an amount to reach a serum concentration in the range of 3 to 10 μM."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 14, wherein said cyclotide is administered in an amount to reach a serum concentration in the range of 4 to 9 μM."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 14, wherein said cyclotide is administered in an amount to reach a serum concentration in the range of 5 to 9 μM."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["A method for immunosuppression, the method comprising administering an effective amount of a mutated cyclotide of claim 1 to a subject in need thereof."],"number":32,"annotation":false,"title":false,"claim":true},{"lines":["A method for immunosuppression, the method comprising administering an effective amount of a mutated cyclotide of claim 2 to a subject in need thereof."],"number":33,"annotation":false,"title":false,"claim":true},{"lines":["A method for immunosuppression, the method comprising administering an effective amount of a cyclotide of claim 3 to a subject in need thereof."],"number":34,"annotation":false,"title":false,"claim":true},{"lines":["A method for immunosuppression, the method comprising administering an effective amount of a mutated cyclotide of claim 4 to a subject in need thereof."],"number":35,"annotation":false,"title":false,"claim":true},{"lines":["A method for immunosuppression, the method comprising administering an effective amount of a mutated cyclotide of claim 5 to a subject in need thereof."],"number":36,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}